Biologic · Combination cell therapy in a biomaterial scaffold; no ChEMBL entity exists, so ChEMBL was NOT queried. CLASS-LEVEL FLAG recorded knowingly: intervention search 'endothelial progenitor cells AND mesenchymal stem cells' returned 10 raw hits, of which only NCT01468064 actually delivers BOTH cell types (autologous bone marrow stromal cells and autologous EPCs, in SEPARATE arms rather than co-embedded). The other 9 (MSC exosomes, ALLO-ASC-DFU follow-ups, exercise mobilisation, allogeneic MSC infusion, bone marrow infusion, stem cells in critical limb ischaemia, 3D bone equivalent) were REJECTED as single-modality or unrelated. NO human trial uses hyaluronic-acid hydrogel co-embedding, hypoxic preconditioning, or kidney-derived MSC; the recorded trial is in ischaemic stroke, not renal injury.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Stroke · Infarction, Middle Cerebral Artery
Enrolment: 20 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Lipopolysaccharide-induced acute kidney injury (endotoxaemia) in mice, with femoral ligation used to assess angiogenesis
Coembedded endothelial progenitor cells with hypoxically preconditioned mesenchymal stem cells gave additive improvement in medullary renal blood flow and proteinuria over endothelial progenitor cells alone, raised circulating M2 macrophages and reduced circulating cytokines and chemokines.
Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.
